WINRHO

This brand name is authorized in United States. It is also authorized in Canada, Hong Kong SAR China, Tunisia, Turkey.

Active ingredients

The drug WINRHO contains one active pharmaceutical ingredient (API):

1	Human normal immunoglobulin G UNII 66Y330CJHS - HUMAN IMMUNOGLOBULIN G
	Human normal immunoglobulin contains mainly immunoglobulin G (IgG) with a broad spectrum of antibodies against infectious agents. Human normal immunoglobulin contains the IgG antibodies present in the normal population. It is usually prepared from pooled plasma from not fewer than 1000 donors.
	Read more about Human normal immunoglobulin G

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
WINRHO SDF Solution for injection	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J06BB01	Anti-D (rh) immunoglobulin	J Antiinfectives for systemic use → J06 Immune sera and immunoglobulins → J06B Immunoglobulins → J06BB Specific immunoglobulins
Discover more medicines within J06BB01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02302551, 02302578, 02302594
HK	Department of Health Drug Office	62857, 62858
TN	Direction de la Pharmacie et du Médicament	3213011
TR	İlaç ve Tıbbi Cihaz Kurumu	8699733980011, 8699733980769, 8699733980776
US	FDA, National Drug Code	70257-300, 70257-310, 70257-330, 70257-350, 70504-3000, 70504-3100, 70504-3300, 70504-3500